168 related articles for article (PubMed ID: 33614284)
1. Abnormal expression of
Wang J; Liu Z; Zhang C; Wang H; Li A; Liu B; Lian X; Ren Z; Zhang W; Wang Y; Zhang B; Pang B; Gao Y
PeerJ; 2021; 9():e10820. PubMed ID: 33614284
[TBL] [Abstract][Full Text] [Related]
2. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
4. ESPL1 Is a Novel Prognostic Biomarker Associated With the Malignant Features of Glioma.
Liu Z; Lian X; Zhang X; Zhu Y; Zhang W; Wang J; Wang H; Liu B; Ren Z; Zhang M; Liu M; Gao Y
Front Genet; 2021; 12():666106. PubMed ID: 34512713
[TBL] [Abstract][Full Text] [Related]
5. CENPA acts as a prognostic factor that relates to immune infiltrates in gliomas.
Wang B; Wei W; Long S; Wang L; Yang B; Wu D; Li Z; Li Z; Arshad M; Li X; Chen J
Front Neurol; 2022; 13():1015221. PubMed ID: 36341103
[TBL] [Abstract][Full Text] [Related]
6. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of
Ren Z; Ma S; Cheng X; Guo Y; Liu Z
Int J Clin Exp Pathol; 2021; 14(9):938-955. PubMed ID: 34646412
[TBL] [Abstract][Full Text] [Related]
8.
Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
Front Immunol; 2022; 13():974346. PubMed ID: 36275718
[TBL] [Abstract][Full Text] [Related]
9. The new oncogene transmembrane protein 60 is a potential therapeutic target in glioma.
Yang F; Zhang X; Wang X; Xue Y; Liu X
Front Genet; 2022; 13():1029270. PubMed ID: 36744183
[TBL] [Abstract][Full Text] [Related]
10. Significantly high expression of NUP37 leads to poor prognosis of glioma patients by promoting the proliferation of glioma cells.
Liu Z; Wang H; Jia Y; Wang J; Wang Y; Bian L; Liu B; Lian X; Zhang B; Ren Z; Zhang W; Dai W; Gao Y
Cancer Med; 2021 Aug; 10(15):5218-5234. PubMed ID: 34264013
[TBL] [Abstract][Full Text] [Related]
11. COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma.
Wang H; Liu Z; Li A; Wang J; Liu J; Liu B; Lian X; Zhang B; Pang B; Liu L; Gao Y
Exp Ther Med; 2021 Nov; 22(5):1224. PubMed ID: 34539820
[TBL] [Abstract][Full Text] [Related]
12. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma.
Dong T; Zhang B; Zhang R; Wang C; Liu X; Wang F; Hao N; Tan K; Chang YZ
Front Oncol; 2022; 12():963096. PubMed ID: 36237302
[TBL] [Abstract][Full Text] [Related]
13. Connective tissue growth factor as an unfavorable prognostic marker promotes the proliferation, migration, and invasion of gliomas.
Song ZB; Yang HP; Xu AQ; Zhan ZM; Song Y; Li ZY
Chin Med J (Engl); 2020 Mar; 133(6):670-678. PubMed ID: 32197031
[TBL] [Abstract][Full Text] [Related]
14. Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients.
Liu Z; Shen F; Wang H; Li A; Wang J; Du L; Liu B; Zhang B; Lian X; Pang B; Liu L; Gao Y
Cell Cycle; 2020 Jul; 19(13):1632-1640. PubMed ID: 32436804
[TBL] [Abstract][Full Text] [Related]
15. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
[TBL] [Abstract][Full Text] [Related]
16. HOXA5 Is Recognized as a Prognostic-Related Biomarker and Promotes Glioma Progression Through Affecting Cell Cycle.
Ding F; Chen P; Bie P; Piao W; Cheng Q
Front Oncol; 2021; 11():633430. PubMed ID: 34485110
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic utility of eIF6 in glioblastoma: a study based on TCGA and CGGA databases.
Liang J; Liu F; Yang Y; Li X; Cai G; Cao J; Zhang B
Am J Transl Res; 2022; 14(7):5040-5049. PubMed ID: 35958479
[TBL] [Abstract][Full Text] [Related]
18. CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma.
Wang F; Zhao F; Zhang L; Xiong L; Mao Q; Liu Y; Qiu X; Wang X; Shui L; Chen X; Ren K; Shui P; Zhang Q; Deng Y; Li W; Xie X; Wu D; Li T; Lang J; Liu L; Chen H; Xu J; Bai S; Li Z; Yue Q; Chen N; Zhou B; Yi C; Wei Y; Fu Y; Luo Y; Gou Q; Liu L; Liu Y; Kang J; Wang J; Jing D; Zhang F; Yang X; Li X; Jiang T; Zhang Z; Zhou Y; Yi J
Mol Cancer; 2022 Jul; 21(1):153. PubMed ID: 35879762
[TBL] [Abstract][Full Text] [Related]
19. CUX1 Facilitates the Development of Oncogenic Properties
Feng F; Zhao Z; Zhou Y; Cheng Y; Wu X; Heng X
Front Mol Biosci; 2021; 8():705008. PubMed ID: 34422906
[No Abstract] [Full Text] [Related]
20. NCAPG as a Novel Prognostic Biomarker in Glioma.
Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
Front Oncol; 2022; 12():831438. PubMed ID: 35280743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
